Paris-based Sanofi (Euronext: SAN) has been forced to walk back claims that the USA would be entitled to the largest order of its investigational COVID-19 vaccine, should it be successfully developed.
French President Emmanuel Macron echoed an angry reaction in the country, even while the vaccine remains in early phases of development.
Chief executive Paul Hudson had reportedly told Bloomberg that the US would be entitled to a greater share of the first orders, given that the country had “invested in taking the risk,” in developing the vaccine.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze